Journal
VIRUSES-BASEL
Volume 13, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/v13050817
Keywords
human cytomegalovirus; latency; antiviral; latent reservoir; shock and kill; F49A-FTP; transplant
Categories
Funding
- Medical Research Council (MRC) Programme Grant [MR/S00081X/1]
- MRC Doctoral Training grant [RG86932]
- MRC [MR/S00081X/1] Funding Source: UKRI
Ask authors/readers for more resources
HCMV can establish lifelong latency in healthy individuals and cause severe disease in immunosuppressed patients. Current antiviral drugs face challenges of poor bioavailability, toxicity, viral resistance, and inability to fully target latent infection. Treatments targeting latent infection are needed to address disease caused by reactivation from latency.
Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus. In healthy people, primary infection is generally asymptomatic, and the virus can go on to establish lifelong latency in cells of the myeloid lineage. However, HCMV often causes severe disease in the immunosuppressed: transplant recipients and people living with AIDS, and also in the immunonaive foetus. At present, there are several antiviral drugs licensed to control HCMV disease. However, these are all faced with problems of poor bioavailability, toxicity and rapidly emerging viral resistance. Furthermore, none of them are capable of fully clearing the virus from the host, as they do not target latent infection. Consequently, reactivation from latency is a significant source of disease, and there remains an unmet need for treatments that also target latent infection. This review briefly summarises the most common HCMV antivirals used in clinic at present and discusses current research into targeting the latent HCMV reservoir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available